Introduction
============

*Streptococcus pyogenes* (group A streptococci/GAS) remains an important human pathogen responsible for a wide variety of invasive and noninvasive infections including pharyngotonsillitis, skin and soft tissue infections and bacteraemia. Macrolides are widely used to treat GAS infections in patients allergic to *β*-lactam antibiotics. The development and spread of macrolide resistance among GAS throughout the world is therefore a major concern.

The drug efflux pump, encoded by the *mef* gene (currently represented by four subclasses A, E, I and O), is one of the most common mechanisms responsible for resistance to 14- and 15-membered macrolides in GAS and other species (Sutcliffe *et al*. [@b16]; Varaldo *et al*. [@b18]). At least three mobile elements carrying the *mef*(A) gene have been identified in GAS: the Tn*1207.3* transposon (Santagati *et al*. [@b12]), the Φ*10394.4* phage chimera (Banks *et al*. [@b1]) and the Φ*m46.1* element (Brenciani *et al*. [@b3]). Studies indicate a significant prevalence of the *mef*(A) gene among GAS isolates in Europe and elsewhere. For instance, nationwide surveillance in Germany noted a frequency of 31% (Bley *et al*. [@b2]), while an Italian study found the prevalence of *mef*(A) among GAS to be 16% (Creti *et al*. [@b4]). Interestingly, there appears to be a skewed distribution of macrolide resistance genes among different GAS strains belonging to different *emm* types. The *mef*(A) gene is most frequently harboured by certain *emm* types such as *emm1*, *emm2*, *emm3*, *emm4*, *emm9*, *emm12* and *emm75*, whereas *emm* types such as *emm*22, *emm*77, *emm*87 and *emm*89 have not yet been documented to carry any *mef* determinant (Creti *et al*. [@b4]; Grivea *et al*. [@b9]; Silva-Costa *et al*. [@b14]; Wajima *et al*. [@b19]). These observations suggest differences in the capacity of GAS *emm* types to acquire *mef* genes, and while the horizontal gene transfer of *mef*(A)-bearing genetic elements has been demonstrated *in vitro* by conjugation (Giovanetti *et al*. [@b8]; Santagati *et al*. [@b12]) and by transduction (Di Luca *et al*. [@b6]), no comparison has yet been made of *mef* gene transfer frequencies among different GAS strains.

The aim of this study therefore was to examine the transfer frequency of *mef*(A)-containing Tn*1207*.*3* to diverse macrolide-susceptible recipients representing a variety of clinically important *emm* types.

Results and discussion
======================

Erythromycin-resistant transconjugants were detected in 21/23 of the tested recipient strains, with mean frequencies of transconjugants ranging from 7·20 × 10^−8^ to 1·13 × 10^−6^ conjugant/recipient (Table[1](#tbl1){ref-type="table"}). Statistical analysis showed that there was a significant difference in the conjugation frequency between strains ([anova]{.smallcaps}, *P* \< 0·001). PCR confirmed that all 85 randomly selected transconjugants were positive for the *mef*(A) gene as well as the 5′ and 3′ junctions of Tn*1207.3-comEC*. All amplicons were of the expected size. Thus, growth on erythromycin-selective plates can be taken as being strongly indicative of *mef*(A) acquisition by the previously susceptible, *mef*A-negative recipient strains and the integration of Tn*1207.3* into the *comEC* locus.

###### 

Strain characteristics and gene transfer frequencies of the *mef*(A)-bearing Tn*1207.3* element (SMH036) to macrolide-susceptible *Strep. pyogenes*

  *emm* type   Recipient       Multilocus sequence type   Site of isolation                 Mean frequencies of three transfers per recipient ± SEM
  ------------ --------------- -------------------------- --------------------------------- ---------------------------------------------------------
  *emm*1       R366            ST28                       Blood                             9·83 × 10^−6 ^± 1·87 × 10^−6^
  R203         ST28            Blood                      1·13 × 10^−6 ^± 6·46 × 10^−7^     
  R057         ST28            Eye                        3·86 × 10^−6 ^± 1·91 × 10^−6^     
  R502         Not available   Blood                      4·23 × 10^−6 ^± 1·85 × 10^−6^     
  *emm*2       R837            ST55                       Blood                             3·17 × 10^−6 ^± 3·52 × 10^−7^
  R007         ST55            Blood                      2·37 × 10^−6 ^± 5·30 × 10^−7^     
  *emm*3       R032            ST315                      Throat                            1·20 × 10^−7 ^± 1·52 × 10^−8^
  R079         ST315           Throat                     9·80 × 10^−7 ^± 1·72 × 10^−7^     
  *emm*4       R317            ST39                       Blood                             4·50 × 10^−7 ^± 4·93 × 10^−8^
  R211         ST39            Blood                      6·47 × 10^−7 ^± 1·05 × 10^−7^     
  R101         ST39            Ear                        6·17 × 10^−6 ^± 3·75 × 10^−7^     
  *emm*9       R480            ST75                       Blood                             9·20 × 10^−7 ^± 1·89 × 10^−7^
  R097         ST75            Pus                        1·60 × 10^−7 ^± 1·53 × 10^−8^     
  *emm*11      R098            ST22                       Blood                             8·13 × 10^−7 ^± 1·67 × 10^−7^
  R693         ST22            Blood                      3·67 × 10^−7 ^± 1·86 × 10^−8^     
  *emm*12      R214            ST36                       Blood                             1·19 × 10^−7 ^± 5·01 × 10^−8^
  R113         ST36            Throat                     3·97 × 10^−7 ^± 4·97 × 10^−8^     
  R044         ST36            Throat                     6·00 × 10^−7 ^± 8·88 × 10^−8^     
  *emm*59      R205            Not available              Blood                             4·36 × 10^−8 ^± 8·60 × 10^−9^
  *emm*77      R054            ST77                       Skin                              \<3·77 × 10^−8^ (none detected)
  R115         ST77            Vagina                     \<1·08 × 10^−8^ (none detected)   
  *emm*81      R202            ST117                      Blood                             3·97 × 10^−7 ^± 1·48 × 10^−7^
  *emm*87      R208            ST62                       Blood                             7·20 × 10^−8 ^± 8·99 × 10^−9^

The association of *emm* type with conjugative frequency is difficult to assess given the number of isolates of each *emm* type was low. However, the data show a trend for higher frequencies of conjugation among *emm*1 and *emm*4, seen in the region of 10^−6^ to 10^−7^ with lower rates seen particularly with the single isolates of *emm*59 and *emm*87, in the region of 10^−9^, Table[1](#tbl1){ref-type="table"}. These patterns correlate well with the observed frequency of *mef*(A) among clinical isolates belonging to these *emm* types, *mef*(A) being highly prevalent among *emm*1 and *emm*4 isolates but having not been reported among *emm*59 and *emm*87 isolates (Creti *et al*. [@b4]; Grivea *et al*. [@b9]; Silva-Costa *et al*. [@b14]; Wajima *et al*. [@b19]). These data also highlight the potential for the emergence of *mef*(A)-mediated resistance in previously susceptible *emm* types. Two isolates, both belonging to *emm*77, did not produce transconjugants above the lower limit of detection, Table[1](#tbl1){ref-type="table"}, suggesting that a low capacity for acquisition exists among *emm77*. This again correlates well with epidemiological data, and *emm77* has not previously been associated with *mef*(A). Interestingly, previous work using transduction also failed to transfer *mefA* into an *emm* 77 isolate (Di Luca *et al*. [@b6]). All seven *emm* types included here and reported previously to harbour the *mef*(A) gene were able to acquire it by conjugation *in vitro*. Taking only the *emm* types for which at least three isolates were included, *emm*1, *emm*4 and *emm*12, the higher mean frequencies of transconjugants seen with *emm*1 and *emm*4 isolates were statistically significant compared to those seen with *emm*12 isolates. This suggests that an association exists between *emm* type and the transfer frequency of Tn*1207.3* but the testing of a larger collection of isolates is needed to explore this further.

Together the results demonstrate that significant variability exists in *mef*(A) gene conjugative transfer rates between *Strep. pyogenes* strains and that this phenomenon may contribute, at least in part, to the different frequencies of *mef*(A) observed among clinical GAS strains. The mechanisms responsible for these differing rates of *mef*A transfer are not known, but M proteins have previously been proposed to act as barriers for horizontal gene exchange and thus may play a role (Schmitz *et al*. [@b13]). Furthermore, we demonstrate potential for the development of *mef*(A)-mediated erythromycin resistance in currently susceptible lineages.

Materials and methods
=====================

Bacterial isolates
------------------

Group A streptococci isolates were collected, as part of a separate study, from two London Hospitals, St. Mary's and Paddington and Hammersmith, between 1993 and 2005 (McGregor and Spratt [@b10]). *mef*(A) recipient strains belonged to the following eleven *emm* types: *emm*1, *emm*2, *emm*3, *emm*4, *emm*9, *emm*11, *emm*12, *emm*59, *emm*77, *emm*81 and *emm*89. Strains were chosen based on their availability for study and because they include some of the most common lineages among clinical disease isolates in Europe (Steer *et al*. [@b15]) (Table[1](#tbl1){ref-type="table"}). They also include lineages with observed differences in their frequency of *mef*(A) prevalence (Creti *et al*. [@b4]; Grivea *et al*. [@b9]; Silva-Costa *et al*. [@b14]; Wajima *et al*. [@b19]). Isolate SMH036 (*emm*75) was used as the Tn*1207.3* donor and carries the Tn*1207.3* element inserted into the *comEC* locus. Discrimination of *mef* gene subclasses A, E, O and I by RFLP analysis confirmed the presence of only *mef*(A) in SMH036. SMH036 was confirmed to be resistant to erythromycin with a MIC of 8 mg l^−1^ and grew readily on 2 mg l^−1^ erythromycin-selective blood plates. It was, however, susceptible to fusidic acid and rifampicin. All recipient strains were confirmed to be susceptible to erythromycin (MIC \< 0·015--0·12 g l^−1^) and unable to grow on selective blood agar plates containing 2 mg l^−1^ erythromycin used in screening for transconjugants. The wild-type recipients were also confirmed to be susceptible to rifampicin and fusidic acid, and resistant derivatives of these, used to differentiate transconjugants from SMH036, were generated by inducing to spontaneous mutations conferring resistance to rifampicin or fusidic acid.

*In vitro* conjugative gene transfer of Tn*1207.3*
--------------------------------------------------

Filter mating was performed according to Giovanetti *et al*. (Giovanetti *et al*. [@b7]). Transconjugants were selected on blood agar plates containing either fusidic acid (25 mg l^−1^) or rifampicin (25 mg l^−1^) in addition to erythromycin (2 mg l^−1^). Transfers were performed in triplicate.

Confirmation of *mef*(A) transfer
---------------------------------

Putative transconjugants were tested for the presence of *mef*(A) by PCR using primers *mef*F/*mef*R as previously described (Sutcliffe *et al*. [@b17]). Both Tn*1207*.*3*/*comEC* junctions were also examined by PCR, primers TnRjF/TnRjR (D'Ercole *et al*. [@b5]) spanning the 5′ junction and *comEC*F/*orf*LF (Santagati *et al*. [@b12]) spanning the 3′ junction. Donor SMH036 was used as a positive control for these PCRs. Transconjugants were randomly selected (3--6 per donor/recipient combination) for PCR validation with a total of *n *= 85. All recipient strains produced no amplicons in these PCRs.
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